| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2026―Jul―06 |
Strategies for antiviral treatment of COVID-19 and post-COVID syndrome: a narrative review of evidence-based approaches and pharmacoeconomic considerations |
S. А. Zykina, А. К. Turizhanova, I. R. Salpagarov, D. А. Polyakova, А. А. Temiev, К. Goyal, et al. (+7) К. R. Nigmatullina, F. I. Kolesova, А. D. Chotchaeva, А. R. Permyakova, D. D. Bogatinova, С. R. Abdullaeva, К. S. Kobtseva |
| 2 |
[GO] |
2023―Jul―20 |
Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy |
M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina |
| 3 |
[GO] |
2023―Apr―24 |
Efficiency of Levilimab in patients with moderate and severe COVID-19 |
Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A. S. Kolbin, et al. (+5) M. V. Livshits, T. A. Usmanova, A. M. Fakhrutdinova, Yu. S. Konstantinova, A. P. Gubanov |
| 4 |
[GO] |
2023―Jan―24 |
Dietary factors influencing the COVID-19 epidemic process |
S. V. Ponomarenko |
| 5 |
[GO] |
2022―Okt―11 |
Funding for coronavirus health worker payments |
I. Yu. Bocharova, A. Yu. Rymanov |
| 6 |
[GO] |
2022―Okt―11 |
Economic burden of the novel coronavirus infection: a systematic review |
V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin, D. F. Gareeva |
| 7 |
[GO] |
2022―Jul―28 |
Clinical study of real-time polymerase chain reaction test kit for SARS-CoV-2 ribonucleic acids detection |
M. Yu. Dmitryukova, A. A. Golod, M. E. Senina, A. E. Gushchin |
| 8 |
[GO] |
2022―Apr―15 |
A systematic review of real-world clinical practice data in COVID-19: non-interventional studies |
S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, V. V. Strizheletsky, I. G. Ivanov |
| 9 |
[GO] |
2021―Okt―08 |
Pharmacoeconomic aspects of COVID-19 treatment |
I. V. Rogova, E. A. Zhidkova, I. A. Popova, A. V. Zaborovskiy, K. G. Gurevich |
| 10 |
[GO] |
2021―Sep―04 |
COVID-19 pandemic prediction model based on machine learning in selected regions of the Russian Federation |
D. V. Gavrilov, R. V. Abramov, А. V. Kirilkina, А. А. Ivshin, R. E. Novitskiy |
| 11 |
[GO] |
2021―Jul―28 |
Impact of disease information (Ebola and COVID-19) on the pharmaceutical sector in Russia and USA |
E. A. Fedorova, D. O. Afanasyev, A. V. Sokolov, M. P. Lazarev |
| 12 |
[GO] |
2021―Jul―28 |
Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy |
I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin, Yu. I. Zhuravlev |
| 13 |
[GO] |
2021―Apr―29 |
Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 |
O. V. Zhukova, A. L. Khokhlov |
| 14 |
[GO] |
2021―Feb―08 |
Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm |
M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov |
| 15 |
[GO] |
2020―Aug―10 |
COVID-19 pandemic: protective role of vitamin D |
O. A. Gromova, I. Yu. Torshin, G. Kh. Gabdulina |
| 16 |
[GO] |
2020―Apr―25 |
Real-time RT-PCR diagnostics of virus causing COVID-19 |
E. V. Goncharova, A. E. Donnikov, V. V. Kadochnikova, S. A. Morozova, M. N. Boldyreva, I. S. Galkina, D. V. Blinov |
| 17 |
[GO] |
2020―Apr―25 |
COVID-19 in Moscow: prognoses and scenarios |
M. V. Tamm |
